Skip to main content
See every side of every news story
Published loading...Updated

Medable, Tufts CSDD value AI gain at $21m net per programme

Summary by Pharmaphorum
New analysis from Tufts CSDD and Medable shows AI agent value to oncological drug development programmes at up to $21m each.

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news on Wednesday, August 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal